A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Trial Profile

A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMpower133
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 31 Jul 2019 to 1 Aug 2019.
    • 03 Jul 2017 Planned primary completion date changed from 31 Jul 2019 to 1 Aug 2019.
    • 08 Jun 2017 Planned number of patients changed from 400 to 500.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top